Substance / Medication

Carglumic acid

Overview

Active Ingredient
carglumic acid
RxNorm CUI
401713
Labeler: Navinta LLCUpdated: 2024-03-23T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

2
Total Trials
0
Recruiting
2
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Valproic acid-induced hyperammonemia with encephalopathy in adults: A meta-analysis.
Huang Tsai-Kuei, Su Yi-Chia, Shih Ching-Sen · Int J Clin Pharmacol Ther · 2025
PMID: 39873559Meta-Analysis
Sodium benzoate for the treatment of hepatic encephalopathy in humans and animals: a systematic review and meta-analysis.
van Zoest Danny, Gal Bram, Agha Ayaz H et al. · Eur J Gastroenterol Hepatol · 2025
PMID: 39975997Meta-AnalysisFull text (PMC)
Continuous renal replacement therapy and survival in acute liver failure: A systematic review and meta-analysis.
Dong Victor, Robinson Andrea M, Dionne Joanna C et al. · J Crit Care · 2024
PMID: 38194760Meta-Analysis
Screening primary carnitine deficiency in 10 million Chinese newborns: a systematic review and meta-analysis.
Zhou Jinfu, Li Guilin, Zeng Yinglin et al. · Orphanet J Rare Dis · 2024
PMID: 38961493Meta-AnalysisFull text (PMC)
Correlation of ammonia and blood laboratory parameters with hepatic encephalopathy: A systematic review and meta-analysis.
Sepehrinezhad Ali, Moghaddam Negin Ghiyasi, Shayan Navidreza et al. · PLoS One · 2024
PMID: 39226259Meta-AnalysisFull text (PMC)
Hyperammonemia After Lung Transplantation: Systematic Review and a Mini Case Series.
Kamel Amir Y, Emtiazjoo Amir M, Adkins Lauren et al. · Transpl Int · 2022
PMID: 35620675Meta-AnalysisFull text (PMC)
Hyperammonemia syndrome post-lung transplantation: Case series and systematic review of literature.
Buzo Bruno Fernando, Preiksaitis Jutta K, Halloran Kieran et al. · Transpl Infect Dis · 2022
PMID: 36039822Meta-Analysis
Hyperammonemia syndrome associated with Ureaplasma spp. Infections in immunocompromised patients and transplant recipients: A systematic review and meta-analysis.
Tantengco Ourlad Alzeus G, De Jesus Federico Cristobal C, Gampoy Eloina Faye S et al. · Clin Transplant · 2021
PMID: 33948993Meta-Analysis
Presentation and management of N-acetylglutamate synthase deficiency: a review of the literature.
Kenneson Aileen, Singh Rani H · Orphanet J Rare Dis · 2020
PMID: 33036647Meta-AnalysisFull text (PMC)
CPS1 T1405N polymorphism, HDL cholesterol, homocysteine and renal function are risk factors of VPA induced hyperammonemia among epilepsy patients.
Chen Lanlan, Tian Qiuxiang, Zhang Miaoran et al. · Epilepsy Res · 2019
PMID: 31151073Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Carglumic acid (substance)
SNOMED CT
412295009
UMLS CUI
C1318649
RxNorm CUI
401713
Labeler
Navinta LLC

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.